Cholera Vaccination Is Back. The World Has Three Years of Catching Up to Do.

For three years, the global stockpile of oral cholera vaccines sat effectively depleted, forcing health authorities to make an impossible triage: vaccinate people already in the middle of an outbreak, or protect communities before the disease arrived. Prevention lost, almost every time. Now, with supply finally recovering, Mozambique has launched the first preventive cholera vaccination campaign since that drought began, with Bangladesh and the Democratic Republic of the Congo lined up to follow. It is a meaningful milestone, but it also reveals just how fragile the architecture of global disease prevention really is.

The oral cholera vaccine, primarily Shanchol and the Euvichol series manufactured by Eubiologics, has long faced a structural mismatch between demand and production capacity. When a major outbreak erupts, reactive campaigns drain whatever buffer exists in the stockpile managed by the International Coordinating Group, the body that governs emergency vaccine access for cholera, meningitis, and yellow fever. Between 2022 and 2024, a convergence of crises, including surging outbreaks across Haiti, Malawi, Syria, and Ethiopia, consumed supply faster than manufacturers could replenish it. The result was a de facto global moratorium on preventive campaigns, the very campaigns that epidemiologists argue are the most cost-effective tool in the cholera control arsenal.

The distinction between reactive and preventive vaccination is not merely semantic. Reactive campaigns, deployed after a disease has already entered a community, are fighting a fire that has already spread. Preventive campaigns, by contrast, build immunity walls in high-risk populations before the pathogen arrives, typically in areas with poor water and sanitation infrastructure where cholera is endemic or seasonally predictable. Research published in The Lancet has consistently shown that oral cholera vaccines, when deployed preventively in high-burden settings, can reduce cases by more than 60 percent over a two-year period.

The three-year gap in preventive campaigning almost certainly contributed to the severity of outbreaks seen globally during that window. Cholera deaths worldwide surged, with the WHO reporting in 2023 that the number of cholera-affected countries had reached its highest level in decades. The DRC alone reported hundreds of thousands of suspected cases. When a system designed to prevent disease is forced into a purely reactive posture, the feedback loop becomes self-reinforcing: outbreaks grow larger, they consume more vaccine, and the stockpile never recovers enough to fund prevention. The system optimizes for crisis response and starves prevention of resources.

Mozambique's new campaign breaks that cycle, at least locally. The country has faced repeated cholera emergencies, including devastating outbreaks following Cyclone Idai in 2019, and its coastal and flood-prone regions remain chronically vulnerable. Deploying vaccines before the next seasonal surge, rather than scrambling after it begins, reflects exactly the kind of upstream intervention that public health experts have long advocated but rarely had the supply to execute.

The recovery of global vaccine supply is genuinely good news, but it comes with a systems-level caution worth naming. The oral cholera vaccine market is dominated by a very small number of manufacturers, and the stockpile remains dependent on donor funding that fluctuates with geopolitical priorities. As foreign aid budgets in the United States and Europe face pressure, the financial scaffolding that supports ICG stockpile replenishment is not guaranteed. A reduction in Gavi, the Vaccine Alliance funding or USAID contributions could compress the stockpile again within a single outbreak season.

There is also a second-order consequence that rarely gets discussed: the resumption of preventive campaigns will generate new data on vaccine effectiveness across diverse epidemiological settings, which could strengthen the evidence base for expanding production commitments. But only if that data is systematically collected and published. In past campaigns, surveillance infrastructure in high-burden countries was too weak to generate the kind of post-campaign effectiveness data that would compel manufacturers to invest in scaling up. Bangladesh, with its comparatively stronger health data systems, may be the most important of the three planned campaigns precisely because it offers the best chance of producing actionable evidence.

Cholera is a disease of infrastructure failure, and vaccines are not a substitute for clean water. But they are the fastest tool available when infrastructure improvements remain decades away for hundreds of millions of people. The question now is whether the world can maintain enough supply discipline to keep prevention on the table, or whether the next cluster of simultaneous outbreaks will drain the stockpile again and reset the clock.